

## **Sonrotoclax and zanubrutinib as frontline treatment for CLL demonstrates high MRD clearance rates with good tolerability: data from an ongoing phase 1/1b study BGB-11417-101**

**Authors:** Romain Guièze,<sup>1</sup> Jacob D. Soumerai,<sup>2</sup> Chan Y. Cheah,<sup>3-5</sup> Mary Ann Anderson,<sup>6,7</sup> Masa Lasica,<sup>8</sup> Emma Verner,<sup>9,10</sup> Stephen S. Opat,<sup>11</sup> Shuo Ma,<sup>12</sup> Robert Weinkove,<sup>13,14</sup> Raul Cordoba,<sup>15</sup> Paolo Ghia,<sup>16,17</sup> Sophie Leitch,<sup>18</sup> David Westerman,<sup>19,20</sup> Sheel Patel,<sup>21</sup> Yiqian Fang,<sup>22</sup> Wei Ding,<sup>21</sup> Constantine S. Tam<sup>23</sup>

**Affiliations:** <sup>1</sup>Estaing University Hospital, Clermont-Ferrand, France; <sup>2</sup>Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA; <sup>3</sup>Sir Charles Gairdner Hospital, Nedlands, WA, Australia; <sup>4</sup>Medical School, University of Western Australia, Crawley, WA, Australia; <sup>5</sup>Linear Clinical Research, Nedlands, WA, Australia; <sup>6</sup>Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; <sup>7</sup>The Walter and Eliza Hall Institute, Melbourne, VIC, Australia; <sup>8</sup>St Vincent's Hospital Melbourne, Fitzroy, VIC, Australia; <sup>9</sup>Concord Repatriation General Hospital, Concord, NSW, Australia; <sup>10</sup>University of Sydney, Sydney, NSW, Australia; <sup>11</sup>Lymphoma Research Group, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia; <sup>12</sup>Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; <sup>13</sup>Te Rerenga Ora Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast & Hutt Valley, Wellington, New Zealand; <sup>14</sup>Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand; <sup>15</sup>Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain; <sup>16</sup>Università Vita-Salute San Raffaele, Milano, Italy; <sup>17</sup>IRCCS Ospedale San Raffaele, Milano, Italy; <sup>18</sup>Te Whatu Ora Health New Zealand-Waitemata, Auckland, New Zealand; <sup>19</sup>Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; <sup>20</sup>University of Melbourne, Melbourne, VIC, Australia; <sup>21</sup>BeiGene USA, Inc, San Mateo, CA, USA; <sup>22</sup>BeiGene (Shanghai) Co, Ltd, Shanghai, China; <sup>23</sup>Alfred Hospital and Monash University, Melbourne, VIC, Australia

### **ABSTRACT**

**Introduction:** BGB-11417-101 (NCT04277637) is an ongoing, first-in-human, phase 1/1b dose-escalation/expansion study in patients with B-cell malignancies. Updated safety and efficacy of sonrotoclax (sonro; BGB-11417) + zanubrutinib (zanu) in treatment-naïve (TN) CLL/SLL are presented.

**Methods:** Patients received zanu (320 mg once daily [QD] or 160 mg twice daily) for 8-12 wk, then added sonro via ramp-up (160 or 320 mg QD). Endpoints included safety, ORR (iwCLL), and minimal residual disease in blood per modified ERIC flow panel (uMRD4).

**Results:** As of 10May2024, 112 patients were enrolled (high TLS risk, 34%; unmutated IGHV, 51%; TP53 mutation, 20%; del(17p), 9%). Median follow-up was 18.3 mo (range, 4.4-29.9). The most common TEAEs were neutropenia (41%), contusion (38%), COVID-19 (30%), and diarrhea (29%). Neutropenia was the most common grade  $\geq 3$  TEAE (26%); 2 patients had a dose reduction/hold, and none discontinued treatment. Two patients (160 mg) had grade 3 febrile neutropenia. No TLS or deaths occurred. Five patients (160 mg) discontinued combination treatment: TEAE, PD, patient withdrawal (n=1 each), elective discontinuation after 96 wk of treatment (n=2); 1 patient (320 mg) discontinued zanu only due to intermittent grade 1 diarrhea. In 108 evaluable patients, ORR was 100% (CR: 160 mg, 41%; 320 mg, 42%). Median time to response was 2.6 mo (range, 1.5-10.8); median time to CR was 8.4 mo (range, 3.9-17.1). Wk 24/48 best blood uMRD4 rates were 61%/79% (sonro 160 mg) and 77%/90% (sonro 320 mg). Median time to uMRD was 9.7 mo (range, 3.9-20.6) with 160 mg and 8.5 mo (range, 5.4-19.9) with 320 mg. No progression was seen in the sonro 320 mg cohort.

**Conclusion:** Sonro + zanu was well tolerated in patients with TN CLL/SLL. Substantial efficacy was observed, with 100% ORR in assessed patients and 90% best uMRD rate in the 320 mg cohort patients who reached 48 wk of therapy. High blood uMRD4 rates occurred early and were sustained. A registrational phase 3 study (CELESTIAL-TNCLL; BGB-11417-301) assessing this combination with sonro 320 mg is recruiting.